Extrusion of Cell Encapsulated in Boron Nitride Nanotubes Reinforced Gelatin-Alginate Bioink for 3D Bioprinting
Kakarla AB., Kong I., Kong C., Irving H., Thomas CJ.
Laboratory Study, published in Gels (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Gels (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 36286104
- PMCID
- PMC9602097
- DOI
- 10.3390/gels8100603
- Citations
- 2
Abstract (original English)
Three-dimensional (3D) bioprinting, an innovative technology, has gained the attention of researchers as a promising technique for the redevelopment of complex tissue or organ structures. Despite significant advancements, a major challenge in 3D bioprinting is the limited number of suitable bioinks that fulfil the physiochemical requirements to produce complicated structures. Therefore, there is a demand for the production of bioinks for 3D bioprinting techniques. In this short communication, THP-1 cells encapsulated in boron nitride nanotubes (BNNTs) reinforced gelatin and alginate bioink was prepared. The study investigated the impact on the cells during printing using a fluorescence cell image. The results showed that the pure polymer bioinks demonstrated poor printability properties with the incorporation of cells. However, BNNT-combined bioink showed a significant increase in structural integrity even after the incorporation of cells. Furthermore, the scaffold structure was successfully printed with the cells incorporated bioink, and a considerable number of live cells were observed. With further studies, BNNTs as a promising nanomaterial for formulating bioink encapsulated with cells can be understood fully.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.